Congenital anomaly of the great arteries
MONDO:0020292Also known as: congenital aorta, aortic arch or pulmonary arteries anomaly
73 clinical trials for this condition and its sub-types, 1 tagged with Congenital anomaly of the great arteries itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Congenital anomaly of the great arteries
-
Aortic arch defects 1 trial · 28 incl. sub-types
7 sub-types
- Takayasu arteritis 27 trials
- Kommerell diverticulum 0 trials
- Neuhauser anomaly 0 trials
- Dysphagia lusoria 0 trials
- Encircling double aortic arch 0 trials
- Persistent fifth aortic arch 0 trials
- Right aortic arch 0 trials
-
Congenital pulmonary valve stenosis 2 trials · 7 incl. sub-types
4 sub-types
- Pulmonic stenosis 5 trials
- Subpulmonary stenosis 0 trials
- Supravalvular pulmonary stenosis 0 trials
- Valvar pulmonary stenosis 0 trials
-
Pulmonary branch stenosis 5 trials
-
1 sub-type
- Congenital pulmonary vein atresia 0 trials
-
Absence of the pulmonary artery 1 trial
-
Aortic arch interruption 0 trials
-
Aorto-ventricular tunnel 0 trials
2 sub-types
- Aorto-left ventricular tunnel 0 trials
- Aorto-right ventricular tunnel 0 trials
-
Fixed subaortic stenosis 0 trials
2 sub-types
- Discrete fibromuscular subaortic stenosis 0 trials
- Tunnel subaortic stenosis 0 trials
-
Primary pulmonary vein stenosis 0 trials
-
Pulmonary artery hypoplasia 0 trials
-
Scimitar syndrome 0 trials
-
A graft that grows? new vessel may spare infants repeat surgeries
Cure Not yet recruitingThis trial tests a new type of blood vessel graft, called ATEV, in infants born with a missing or disconnected pulmonary artery. The graft is designed to reconnect the heart to the lungs and grow as the child grows, potentially avoiding future surgeries. The study will evaluate s…
Phase 1/2 • Sponsor: Joseph Dearani • Aim: Cure
Last updated Aug 27, 2026 00:00 UTC
-
Can a new heart valve offer lasting relief for pulmonary stenosis?
Disease control Not yet recruitingThis study follows people with moderate to severe pulmonary regurgitation or stenosis who receive the PULSTA transcatheter pulmonary valve, a less invasive option for replacing a faulty heart valve. Researchers will track how well the valve works over time, measuring improvements…
Sponsor: Taewoong Medical Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New dissolving stent could spare kids repeated heart surgeries
Disease control Not yet recruitingThis trial tests a new type of stent that dissolves over time for children under 9 with narrowed arteries in or near the heart. The stent opens the vessel and then gradually disappears, allowing the artery to grow naturally. The study will enroll 45 children and follow them for 5…
Sponsor: PediaStent LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug aims to tame rare artery disease
Disease control Not yet recruitingThis phase 2 trial tests whether secukinumab, a drug that blocks IL-17A, can help people with active severe Takayasu arteritis achieve remission and stop taking steroids. About 52 participants will receive either secukinumab injections or standard care (like TNF inhibitors). The …
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to tame rare artery disease
Disease control Not yet recruitingThis study tests two new drugs, vunakizumab and ivarmacitinib, for people with active Takayasu arteritis (TAK), a rare disease that causes inflammation in large blood vessels. The trial will enroll 180 adults aged 18-70 whose disease is still active despite standard treatments. R…
Phase 4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Could a lung drug fix blood vessel damage in rare artery disease?
Disease control Not yet recruitingThis study tests whether adding pirfenidone, a drug used for lung and liver scarring, to standard treatment can improve blood vessel damage in people with Takayasu arteritis. About 92 adults aged 18-60 will receive either pirfenidone or a placebo for 6 months. The goal is to see …
Phase 4 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New Total-Body PET scanner could revolutionize vasculitis diagnosis
Diagnosis Not yet recruitingThis study will test a new type of PET/CT scanner, called Long-Axial Field-of-View (LAFOV), to see if it can provide clearer images of blood vessel inflammation in people with large vessel vasculitis (LVV). The scanner is more sensitive and can image the whole body faster, potent…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Immune clues in the blood may foretell heart trouble
Knowledge-focused Not yet recruitingThis study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New ultrasound score may better monitor rare artery disease
Knowledge-focused Not yet recruitingThis study will test whether a special ultrasound score, called OTUS, can accurately track disease activity in people with Takayasu arteritis, a rare condition that causes inflammation of the large arteries. Researchers will follow 100 patients with active disease, performing ult…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC